Faculty profile

Sylvie Mader

ResearcherBiochimie et médecine moléculaireUniversité de Montréal

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a Université de Montréal directory, so their courses may be missing. Find their university profile.

Sylvie Mader

Researcher

Biochimie et médecine moléculaire

Université de Montréal

Montreal, Quebec, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
5 publications in the last five years, latest in 2026.
Senior (last) author on 2 recent papers, a sign of leading a research group.
Principal investigator on 14 research grants (7 CIHR, 6 NSERC, 1 SSHRC), most recently in 2024.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

Collaborators

Grants

Publications by year

Counts cover the publications linked to this profile. Citations and the h-index appear when the source records them.

Profiles and links

Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Breast Cancer Antiestrogens Estrogen Receptor Sumoylation Ubiquitination Chromatin epithelial differentiation epithelial to mesenchymal transition

Latest papers

A Chemical-Genetic Interaction Matrix Reveals Drug Mechanism and Genetic Architecture.
bioRxiv : the preprint server for biology · 2026
IDH2 Inhibitors Gain a Wildcard Status in the Cancer Therapeutics Competition.
Cancers · 2024 · senior author
The AF-2 cofactor binding region is key for the selective SUMOylation of estrogen receptor alpha by antiestrogens.
The Journal of biological chemistry · 2023 · senior author

All 24 publications

Latest funding

Oncolytic virotherapy against triple-negative breast cancer: harnessing heterogenous viral sensitivities to improve treatment efficacy
CIHR · 2025 · Co-investigator
$1,120,725
Role of IDH2 in the metabolic plasticity of breast epithelial cells
NSERC · 2024 · Principal investigator
$25,000
Live cell imaging platform for the mechanistic analysis of cell differentiation, migration and division
NSERC · 2024 · Principal investigator
$150,000

All 22 grants and awards

24 publications.

A Chemical-Genetic Interaction Matrix Reveals Drug Mechanism and Genetic Architecture.

Coulombe-Huntington J, Bertomeu T, Huard C, Chatr-Aryamontri A, St-Cyr DJ, Sánchez-Osuna M, Papadopoli D, Normandin K, Paydar M, McLaughlan S, St-Denis C, Zhang L, Say H, Palou R, Stark C, Breitkreutz BJ, van der Sloot AM, Manohar S, Lavoie H, Borden KLB, Raught B, D'Amours D, Sicheri F, Verreault A, Mader S, Meloche S, Therrien M, Thibault P, Wilhelm B, Dirks PB, Aitchison JD, Patton E, King RW, Roux PP, Sauvageau G, Hoang T, Marinier A, Harrington L, Kwok B, Archambault V, Topisirovic I, Tyers M

bioRxiv : the preprint server for biology2026

DOI: 10.64898/2026.01.28.701823 PMID: 41659671

IDH2 Inhibitors Gain a Wildcard Status in the Cancer Therapeutics Competition.

Piva R, Gharari N, Labrador M, Mader S

Cancers2024Senior author

DOI: 10.3390/cancers16193280 PMID: 39409901

The AF-2 cofactor binding region is key for the selective SUMOylation of estrogen receptor alpha by antiestrogens.

Vallet A, El Ezzy M, Diennet M, Haidar S, Bouvier M, Mader S

The Journal of biological chemistry2023Senior author

DOI: 10.1016/j.jbc.2022.102757 PMID: 36460099

Estrogens desensitize MCF-7 breast cancer cells to apelin-induced autophagy and enhanced growth under estrogen starvation: a possible implication in endocrine resistance.

Bouchelaghem R, Mader S, Gaboury L, Messarah M, Boumendjel M, Boumendjel A

Cellular and molecular biology (Noisy-le-Grand, France)2022

DOI: 10.14715/cmb/2022.68.9.18 PMID: 36905266

Dual-function antiandrogen/HDACi hybrids based on enzalutamide and entinostat.

Barrett RRG, Nash C, Diennet M, Cotnoir-White D, Doyle C, Mader S, Thomson AA, Gleason JL

Bioorganic & medicinal chemistry letters2022

DOI: 10.1016/j.bmcl.2021.128441 PMID: 34767912

Positive Regulation of Estrogen Receptor Alpha in Breast Tumorigenesis.

Porras L, Ismail H, Mader S

Cells2021Senior author

DOI: 10.3390/cells10112966 PMID: 34831189

From Micro to Long: Non-Coding RNAs in Tamoxifen Resistance of Breast Cancer Cells.

Barazetti JF, Jucoski TS, Carvalho TM, Veiga RN, Kohler AF, Baig J, Al Bizri H, Gradia DF, Mader S, Carvalho de Oliveira J

Cancers2021

DOI: 10.3390/cancers13153688 PMID: 34359587

Role of SUMOylation in differential ERα transcriptional repression by tamoxifen and fulvestrant in breast cancer cells.

Traboulsi T, El Ezzy M, Dumeaux V, Audemard E, Mader S

Oncogene2019Senior author

DOI: 10.1038/s41388-018-0468-9 PMID: 30190545

Monitoring ligand-dependent assembly of receptor ternary complexes in live cells by BRETFect.

Cotnoir-White D, El Ezzy M, Boulay PL, Rozendaal M, Bouvier M, Gagnon E, Mader S

Proceedings of the National Academy of Sciences of the United States of America2018Senior author

DOI: 10.1073/pnas.1716224115 PMID: 29487210

MCM2: An alternative to Ki-67 for measuring breast cancer cell proliferation.

Yousef EM, Furrer D, Laperriere DL, Tahir MR, Mader S, Diorio C, Gaboury LA

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc2017

DOI: 10.1038/modpathol.2016.231 PMID: 28084344

Oncolytic virotherapy against triple-negative breast cancer: harnessing heterogenous viral sensitivities to improve treatment efficacy

Co-investigatorCIHR2025Project Grant

Principal investigators: Bourgeois-Daigneault, Marie-Claude

Keywords: Breast Cancer; Molecular Tnbc Subtypes; Oncolytic Virus; Therapy; Triple-Negative Breast Cancer; Vesicular Stomatitis Virus

$1,120,725

Role of IDH2 in the metabolic plasticity of breast epithelial cells

Principal investigatorNSERC2024International - Catalyst

Principal investigators: Mader, Sylvie

Keywords: Advancement of knowledge; Human health (including medically-related psychological research)

$25,000

Live cell imaging platform for the mechanistic analysis of cell differentiation, migration and division

Principal investigatorNSERC2024Research Tools and Instruments

Principal investigators: Mader, Sylvie

Keywords: Biosensors; Cell differentiation; Cell division; Cell migration; Fluorescence; Live cell imaging; Morphogensis; Protein expression; Protein stability; Subcellular localization of proteins

$150,000

Exploiting Electrolytic Gating in Graphene Field-Effect Nanosensors to Achieve Multiplexed Breast Cancer Profiling for Personalized Medicine

Co-investigatorSSHRC2024New Frontiers in Research Fund - Exploration

Principal investigators: Bouilly, Delphine

$125,000

Mechanisms of action of antiestrogens in breast cancer: roles of ubiquitin-like modifications in transcriptional inactivation of Estrogen Receptor alpha.

Nominated PICIHR2023Project Grant

Principal investigators: Mader, Sylvie N

Keywords: Antiestrogens; Breast Cancer; Chromatin; Cofactors; Drug Design; Estrogen Receptor; Proteomics; Sumoylation; Transcription; Ubiquitination

$841,500

Mechanisms of action of Grainy Head Like transcription factors in mammary epithelial differentiation

Principal investigatorNSERC2023Discovery Grants Program - Individual

Principal investigators: Mader, Sylvie

Keywords: epithelial differentiation; mammary epithelial cells; progenitors; transcription factors; grainy-head like transcription factors; transcriptional cofactors; epithelial to mesenchymal transition; normal human mammary gland

$104,000

Mechanisms of action of antiestrogens in breast cancer: roles of Ubi-like modifications in transcriptional inactivation of Estrogen Receptor alpha.

Nominated PICIHR2022Project Grant - PA: Breast Cancer Research

Principal investigators: Mader, Sylvie N

Keywords: Antiestrogens; Breast Cancer; Chromatin; Cofactors; Drug Design; Estrogen Receptor; Proteomics; Sumoylation; Transcription; Ubiquitination

$100,000

Recruitment of SUMO E3 ligases as a new paradigm for transcription factor inactivation

Principal investigatorSSHRC2020New Frontiers in Research Fund - Exploration

Principal investigators: Mader, Sylvie

Keywords: transcription factors Sumoylation hybrid drugs chromatin in silico screens

$250,000

Mechanisms of action of antiestrogens: towards improved treatment of relapse in ER+ breast cancer

Nominated PICIHR2017Project Grant

Principal investigators: Mader, Sylvie N

Keywords: Antiestrogens; Bioluminescence Resonance Energy Transfer; Breast Cancer; Chromatin; Combination Therapies; Estrogen Receptor; Molecular And Cellular Biology; Pharmacology; Structure Function Analyses; Transcriptional Regulation

$745,875

Mechanisms controlling estrogen receptor alpha expression and activity in breast tumorigenesis

Nominated PICIHR2016Project Grant

Principal investigators: Mader, Sylvie N

Keywords: Breast Cancer; Cell Models; Chip-Seq; Crispr-Cas9; Estrogen Receptor Alpha; Functional Genomics; High Throughput Screens; Shrnas; Transcriptomes; Xenografts

$910,350

From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.

Something wrong or missing on this profile? Suggest a correction

Sylvie Mader

Research

Latest papers

Latest funding

A Chemical-Genetic Interaction Matrix Reveals Drug Mechanism and Genetic Architecture.

IDH2 Inhibitors Gain a Wildcard Status in the Cancer Therapeutics Competition.

The AF-2 cofactor binding region is key for the selective SUMOylation of estrogen receptor alpha by antiestrogens.

Estrogens desensitize MCF-7 breast cancer cells to apelin-induced autophagy and enhanced growth under estrogen starvation: a possible implication in endocrine resistance.

Dual-function antiandrogen/HDACi hybrids based on enzalutamide and entinostat.

Positive Regulation of Estrogen Receptor Alpha in Breast Tumorigenesis.

From Micro to Long: Non-Coding RNAs in Tamoxifen Resistance of Breast Cancer Cells.

Role of SUMOylation in differential ER&#x3b1; transcriptional repression by tamoxifen and fulvestrant in breast cancer cells.

Monitoring ligand-dependent assembly of receptor ternary complexes in live cells by BRETFect.

MCM2: An alternative to Ki-67 for measuring breast cancer cell proliferation.

Oncolytic virotherapy against triple-negative breast cancer: harnessing heterogenous viral sensitivities to improve treatment efficacy

Role of IDH2 in the metabolic plasticity of breast epithelial cells

Live cell imaging platform for the mechanistic analysis of cell differentiation, migration and division

Exploiting Electrolytic Gating in Graphene Field-Effect Nanosensors to Achieve Multiplexed Breast Cancer Profiling for Personalized Medicine

Mechanisms of action of antiestrogens in breast cancer: roles of ubiquitin-like modifications in transcriptional inactivation of Estrogen Receptor alpha.

Mechanisms of action of Grainy Head Like transcription factors in mammary epithelial differentiation

Mechanisms of action of antiestrogens in breast cancer: roles of Ubi-like modifications in transcriptional inactivation of Estrogen Receptor alpha.

Recruitment of SUMO E3 ligases as a new paradigm for transcription factor inactivation

Mechanisms of action of antiestrogens: towards improved treatment of relapse in ER+ breast cancer

Mechanisms controlling estrogen receptor alpha expression and activity in breast tumorigenesis

Frequent collaborators

Pierre Thibault

Claude Perreault

Trang Hoang

Nicolas Moitessier

Anne Marinier

Brian Raught

Alain Verreault

Damien D'Amours

Sylvain Meloche

Ivan Topisirovic

Guy Sauvageau

Marc Therrien

Caroline Diorio

Alain Bitton

Brian Wilhelm

Vincent Archambault

Etienne Gagnon

Etienne Caron

Frank Sicheri

Role of SUMOylation in differential ERα transcriptional repression by tamoxifen and fulvestrant in breast cancer cells.